Infection

, Volume 40, Issue 2, pp 153–161

Vaccination against pandemic H1N1 (2009) in patients after allogeneic hematopoietic stem cell transplantation: a retrospective analysis

  • D. Roll
  • J. Ammer
  • B. Holler
  • B. Salzberger
  • B. Schweiger
  • W. Jilg
  • R. Andreesen
  • M. Edinger
  • D. Wolff
  • E. Holler
Clinical and Epidemiological Study
  • 188 Downloads

Abstract

Purpose

Limited data are available on immunologic responses to primary pandemic H1N1 (2009) vaccination in recipients of allogeneic hematopoietic stem cell transplantation (HSCT) recipients. In 2009 serologic responses to either pandemic H1N1 (2009) vaccine (n = 36) or pandemic H1N1 (2009) infection (n = 2) were studied in 38 HSCT recipients.

Methods

Responses were measured with a standard hemagglutination-inhibition assay. Fourteen patients had active chronic graft-versus-host disease (cGvHD) at the time of vaccination/infection and seven patients had cGvHD in remission; 11 patients had no immunosuppressive therapy, and 27 patients were on immunosuppressive therapy. Nineteen patients (53%) responded to pandemic H1N1 (2009) vaccination. Two patients had pandemic H1N1 (2009) infection without prior vaccination, and one patient had severe pandemic H1N1 (2009) infection with acute respiratory distress syndrome despite prior single vaccination.

Results

Non-responders to pandemic H1N1 (2009) vaccination more often had cGvHD (65 vs. 53%) and received second- or third-line therapy (53 vs. 11%), while responders mostly had first-line therapy for cGvHD. While vaccine responders had no or single agent immunosuppressive therapy, non-responders frequently received moderate or intense immunosuppressive therapy. All vaccine recipients previously treated with rituximab were non-responders.

Conclusions

In summary, the overall response to pandemic H1N1 (2009) vaccination in HSCT recipients was modest. Patients receiving combined immunosuppressive therapy for steroid-refractory cGvHD barely responded to pandemic H1N1 (2009) vaccination.

Keywords

Hematopoietic stem cell transplantation GvHD Vaccination Influenza Rituximab 

References

  1. 1.
    Michaelis M, Doerr HW, Cinatl J Jr. An influenza A H1N1 virus revival—pandemic H1N1/09 virus. Infection. 2009;37:381–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Reinheimer C, Allwinn R, Doerr HW. Limited prevalence of influenza A/H1N1v antibodies: footprints of the pandemic of 2010. Infection. 2011;39:101–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360:2605–15.CrossRefGoogle Scholar
  4. 4.
    Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361:680–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Harris KM, Maurer J, Kellermann AL. Influenza vaccine—safe, effective, and mistrusted. N Engl J Med. 2010;363:2183–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis. 2010;16:1068–75.PubMedCrossRefGoogle Scholar
  7. 7.
    Wei JY, Chen FF, Jin J, et al. Novel influenza A (H1N1) in patients with hematologic disease. Leuk Lymphoma. 2010;51:2079–83.PubMedCrossRefGoogle Scholar
  8. 8.
    Seiter K, Nadelman RB, Liu D, et al. Novel Influenza A (H1N1) in patients with hematologic malignancies. J Clin Oncol. 2010;28:27–9.CrossRefGoogle Scholar
  9. 9.
    Espinosa-Aguilar L, Green JS, Forrest GN, et al. Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers experiences. Biol Blood Marrow Transpl. 2011;17:566–73.CrossRefGoogle Scholar
  10. 10.
    Choi SM, Boudreault AA, Xie H (2011) Differences in clinical outcomes following 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 117:5050–6.Google Scholar
  11. 11.
    Hilgendorf I, Jilg W, Einsele H, et al. Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the International Consensus Conference on Clinical Practice in chronic GVHD. Vaccine. 2011;29:2825–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Garland P, de Lavallade H, Sekine T, et al. Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation. Biol Blood Marrow Transpl. 2011;17:632–9.CrossRefGoogle Scholar
  13. 13.
    Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transpl. 2011;17:434–8.CrossRefGoogle Scholar
  14. 14.
    Redelman-Sidi G, Sepkowitz KA, Huang CK, et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. J Infect. 2010;60:257–63.PubMedCrossRefGoogle Scholar
  15. 15.
    Engelhard D, Zakay-Rones Z, Shapira MY, et al. The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1) v-like virus vaccine during the 2009 pandemic. Vaccine. 2011;29:1777–82.PubMedCrossRefGoogle Scholar
  16. 16.
    Filipovich AH. Diagnosis and manifestations of chronic graft-versus-host disease. Best Pract Res Clin Haematol. 2008;21:251–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transpl. 1995;15:825–8.Google Scholar
  18. 18.
    Mitchell SA, Kline Leidy N, Mooney KH, et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Bone Marrow Transpl. 2009;45:762–9.CrossRefGoogle Scholar
  19. 19.
    Allwinn R, Geiler J, Berger A, et al. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is prevalence rate of protecting antibodies in humans? Med Microbiol Immunol. 2010;199:117–21.PubMedCrossRefGoogle Scholar
  20. 20.
    Greenberg ME, Lai MH, Hartel GF, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Plennevaux E, Sheldon E, Blatter M, et al. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet. 2010;375:41–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Mackay HJ, McGee J. Villa D: evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment. J Clin Virol. 2011;50:212–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Lu CC, Wang YC, Lai JH, et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus. Safety ImmunVaccine. 2011;29:444–50.Google Scholar
  24. 24.
    Pollyea DA, Brown JMY, Horning S. Utility of influenza vaccination for oncology patients. J Clin Oncol. 2010;28:2481–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato-oncological disorders. Leuk Lymphoma. 1999;32:369–74.PubMedGoogle Scholar
  26. 26.
    Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. British J Haematol. 2005;130:96–8.CrossRefGoogle Scholar
  27. 27.
    Gueller S, Allwinn R, Mousset S, et al. Enhanced immune response after a second dose of an AS03-adjuvanted H1N1 influenza A vaccine in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17:1546–50.Google Scholar
  28. 28.
    Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Guidelines. Bone Marrow Transpl. 2009;44:521–6.CrossRefGoogle Scholar
  29. 29.
    Takata T, Suzumiya J, Ishikawa T, et al. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-Cell lymphoma after the administration of Rituximab-CHOP. J Clin Exp Hematopathol. 2009;49:9–13.CrossRefGoogle Scholar
  30. 30.
    Pollyea DA, Brown JMY, Horning S. Utility of influenza vaccination for oncology patients. J Clin Oncol. 2010;28:2481–90.PubMedCrossRefGoogle Scholar
  31. 31.
    van Assen S, Holvast A, Benne CA. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthr Rheum. 2010;62:75–81.CrossRefGoogle Scholar
  32. 32.
    Frasca D, Diaz A, Romero M, et al. Intrinsic defects in B cell response to seasonal influenza vaccination in elderly humans. Vaccine. 2010;28:8077–84.PubMedCrossRefGoogle Scholar
  33. 33.
    Greinix HT, Pohlreich D, Kouba M. Elevated numbers of immature/transitional CD21-B lymphocytes and deficiency of memory CD27 + B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2008;14:208–19.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • D. Roll
    • 1
  • J. Ammer
    • 1
  • B. Holler
    • 1
  • B. Salzberger
    • 2
  • B. Schweiger
    • 3
  • W. Jilg
    • 4
  • R. Andreesen
    • 1
  • M. Edinger
    • 1
  • D. Wolff
    • 1
  • E. Holler
    • 1
  1. 1.Department of Hematology and OncologyUniversity of RegensburgRegensburgGermany
  2. 2.Department of Internal Medicine IUniversity of RegensburgRegensburgGermany
  3. 3.Robert Koch InstituteBerlinGermany
  4. 4.Department of Medical Microbiology and HygieneUniversity of RegensburgRegensburgGermany

Personalised recommendations